Retinoids in Cutaneous T Cell Lymphomas
Dermatologica · 09.10.2009 · 145-150
DOI: 10.1159/000248873 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Dermatologica, online erschienen am 09.10.2009. Verfasst von G Mahrle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Universitäts-Hautklinik, Köln, FRG. Die Arbeit wurde bisher 21-mal zitiert (Crossref).
Abstract (Originalsprache)
Sixteen patients – 12 with cutaneous T cell lymphoma (CTCL), 1 with Sézary syndrome, 1 with actinic reticuloid, and 2 with parapsoriasis variegata – were treated with either a new, potent arotinoid alone or with combined etretinate (Tigason®) and PUVA therapy (Re-PUVA). 92% of all patients showed a minor up to a distinct response of their skin lesions within 12.6 ± 7.4 weeks. More than 50% of the skin lesions cleared in 67% of the patients. After discontinuation of the retinoid therapy, relapses occurred in all cases within 3–10 weeks. There was no difference between the therapeutic efficacy of arotinoid alone and the Re-PUVA regimen, but the latter was less toxic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Universitäts-Hautklinik, Köln, FRG.
Zitieren
APA
Mahrle, G., & Thiele, B. (2009). Retinoids in Cutaneous T Cell Lymphomas. Dermatologica, 145-150. https://doi.org/10.1159/000248873
Vancouver
Mahrle G, Thiele B. Retinoids in Cutaneous T Cell Lymphomas. Dermatologica. 2009:145-150. doi:10.1159/000248873
BibTeX
@article{Mahrle2009,
author = {Mahrle, G and Thiele, B},
title = {Retinoids in Cutaneous T Cell Lymphomas},
journal = {Dermatologica},
year = {2009},
pages = {145--150},
doi = {10.1159/000248873}
}
EUVIMED